

**Table S1.** Risk of bias– evaluation of articles according to method applied by Wiebe A., et al., 2022 [21].

Study	Study population	Drug and dose	Study quality								
Authors	N	mg/d	control	randomization	pre-post comparison	follow-up	registration	experimenter-blinding	analyst-blinding	participant-blinding	overall %
Laan [22]	70	Aspirin 1000	+	+	+	+	+	+	+	+	0
Sommer [23]	61	Simvastatin 40	+	+	+	-	+	+	+	+	12.5
Shen [24]	339*										
Vincenzi [25]	24	Pravastatin 40	+	+	+	-	+	-	-	-	50
Ghanizadeh [26]	36	Lovastatin 20	+	+	+	-	+	+	+	+	12.5
Tajik-Esmaeeli [27]	33	Simvastatin 40	+	+	+	?	+	+	+	+	12.5
Chaudhry [28]	108	Simvastatin 40	+	+	+	-	+	+	+	-	25
Sayyah [29]	40	Atorvastatin 20	+	+	+	-	-	+	-	-	50
Deakin	98	Simvastatin 40	+	+	+	-	+	-	?	-	50

[30]												
Berk [31]	40	N-acetylcysteine 1g/b.i.d.	+	+	+	+	+	+	+	+	+	0
Farokhnia [32]	42	N-acetylcysteine 2g	+	+	+	?	+	+	+	+	+	12.5
Sepehrmanesh [33]	42	N-acetylcysteine 1200 mg	+	+	+	?	+	+	+	+	+	12.5
Iranpour [34]	40	Pioglitazone 30 mg/d	+	+	+	-	+	+	+	+	+	12.5
Cakici [35]*	253											
Kulkarni [36]	36	Estrogens 100 mdg (patch)	+	+	+	-	N/A	+	+	+	+	25
Kulkarni [37]	56	Estradiol 100µg transdermal	+	+	+	-	+	+	+	+	+	25
Kulkarni [38]	53	Estradiol 2 mg, Orally	+	+	+	-	-	+	+	+	+	25
Akhondzadeh [39]	32		+	+	+	-	N/A	+	+	+	+	25

[illegible]

Lucena [48]	10	Memantine 20 mg/d	+	+	+	-	+	+	+	+	12.5
Lieberman [49]	70	Memantine 20 mg/d	+	+	+	-	+	+	+	+	12.5
Lee [50]	26	Memantine 20 mg/d	+	+	+	-	+	+	+	+	12.5
Rezaei et [51]	40	Memantine 20 mg/d	+	+	+	-	+	+	+	+	12.5
Omranifard [52]	32	Memantine 20 mg/d	+	+	+	-	+	+	+	+	12.5
Fakhri [53]	30	Memantine 20 mg/d	+	+	+	-	+	+	+	+	12.5
Veerman [54] **	26	Memantine 20 mg/d	+	+	+	-	+	+	+	+	12.5
Mazinani [55]	23	Memantine 20 mg/d	+	+	+	+	+	+	+	+	0
Zheng [56]*	184										
	30	Ondansetron	+	+	+	-	+	+	+	+	12.5

Akhondzadeh [57]		8 mg/d										
Chaudhry [28]	36	Ondansetron 8 mg/d	+	+	+	-	+	+	+	+		12.5
Kulkarni [58]	42	Ondansetron 8 mg/d	+	+	+	-	+	+	+	+		12.5
Samadi [59]	18	Ondansetron 4-8 mg/d	+	+	+	-	+	+	+	+		12.5
Zhang [60]	58	Ondansetron 8 mg/d	+	+	+	-	+	+	+	+		12.5
Fan [61]	61	Telmisartan 80 mg/d	+	+	+	+	+	+	+	+	+	0

\*- meta-analysis, which includes RCT. Each RCT is evaluated separately.

\*\* - crossover study

Based on the Yes/No- criteria, a risk of bias score was evaluated by calculating the percentage of unfulfilled criteria. 0% RoB indicates a high study quality and a 100% RoB a low study quality.